Device choice has long been a driver of sales of certain inhaled therapies, especially those available in multiple inhalers. With generic LAMAs and LABA/ICS FDCs anticipated to launch in the United States, devices may become an even more important driver of physician choice among respiratory therapies. Surveyed and interviewed practitioners note that while insurance often constrains their prescribing options, the device used with a therapy is an important driver and will become even more important as generic drug/device combinations become available. Unmet needs in the device market remain, especially for simpler devices and improved lung deposition.
Markets covered: United States
Primary research: Survey of 60 U.S. pulmonologists fielded in March 2017
Key companies: GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, Teva, Mylan, Propeller Health
Key drugs: Spiriva HandiHaler, Spiriva Respimat, Anoro Ellipta, Brovana, Symbicort HFA, Advair HFA, Advair Diskus